Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Nelson Hayes

Showing results (91-100 of 161) with videos related to

Pageof 17
Sort By:
Journal of Gastroenterology|October 19, 2018
Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failuresMitsutaka Osawa, Michio Imamura, Yuji Teraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 9, 2020
Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patientsYuko Nagaoki, Michio Imamura, Yuji Teraoka, et al.
Journal of Hepatology|April 8, 2015
Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5ASakura Akamatsu, C Nelson Hayes, Hidenori Ochi, et al.
Cancer Medicine|March 8, 2024
Clinicopathological and genomic features of superficial esophageal squamous cell carcinomas in nondrinker, nonsmoker femalesMotomitsu Fukuhara, Yuji Urabe, Hikaru Nakahara, et al.
Journal of Gastroenterology|February 22, 2012
IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patientsMayu Ohnishi, Masataka Tsuge, Tomohiko Kohno, et al.
JCO Clinical Cancer Informatics|December 18, 2024
Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest ModelHikaru Nakahara, Atsushi Ono, C Nelson Hayes, et al.
The Journal of General Virology|March 12, 2010
HBx protein is indispensable for development of viraemia in human hepatocyte chimeric miceMasataka Tsuge, Nobuhiko Hiraga, Rie Akiyama, et al.
Medicine|September 17, 2024
Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinomaRyoichi Miura, Atsushi Ono, Shigeki Yano, et al.
The Journal of General Virology|January 14, 2011
IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populationsHidenori Ochi, Toshiro Maekawa, Hiromi Abe, et al.
Plos One|March 3, 2017
Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virusEisuke Miyaki, Nobuhiko Hiraga, Michio Imamura, et al.
Pageof 17

Showing results (91-100 of 161) with videos related to

Sort By:
Pageof 17
Journal of Gastroenterology|October 19, 2018
Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failuresMitsutaka Osawa, Michio Imamura, Yuji Teraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 9, 2020
Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patientsYuko Nagaoki, Michio Imamura, Yuji Teraoka, et al.
Journal of Hepatology|April 8, 2015
Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5ASakura Akamatsu, C Nelson Hayes, Hidenori Ochi, et al.
Cancer Medicine|March 8, 2024
Clinicopathological and genomic features of superficial esophageal squamous cell carcinomas in nondrinker, nonsmoker femalesMotomitsu Fukuhara, Yuji Urabe, Hikaru Nakahara, et al.
Journal of Gastroenterology|February 22, 2012
IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patientsMayu Ohnishi, Masataka Tsuge, Tomohiko Kohno, et al.
JCO Clinical Cancer Informatics|December 18, 2024
Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest ModelHikaru Nakahara, Atsushi Ono, C Nelson Hayes, et al.
The Journal of General Virology|March 12, 2010
HBx protein is indispensable for development of viraemia in human hepatocyte chimeric miceMasataka Tsuge, Nobuhiko Hiraga, Rie Akiyama, et al.
Medicine|September 17, 2024
Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinomaRyoichi Miura, Atsushi Ono, Shigeki Yano, et al.
The Journal of General Virology|January 14, 2011
IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populationsHidenori Ochi, Toshiro Maekawa, Hiromi Abe, et al.
Plos One|March 3, 2017
Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virusEisuke Miyaki, Nobuhiko Hiraga, Michio Imamura, et al.
Pageof 17